Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707851 | 0.90 | BTK (0.80) | BTKCLK2 | |
| SCHEMBL16013510 | 0.90 | BTK (0.83) | BTKCLK2 | |
| SCHEMBL695204 | 0.89 | BTK (0.70) | BTKCLK2 | |
| SCHEMBL15889144 | 0.87 | BTK (0.53) | BTKCLK2 | |
| SCHEMBL13154174 | 0.85 | BTK (0.73) | BTKCLK2 | |
| SCHEMBL16014325 | 0.85 | BTK (0.82) | BTKCLK2 | |
| SCHEMBL709929 | 0.85 | BTK (0.69) | BTKCLK2 | |
| SCHEMBL19594275 | 0.84 | BTK (0.60) | BTKCLK2 | |
| SCHEMBL13139723 | 0.82 | BTK (0.68) | BTKCLK2 | |
| SCHEMBL19594126 | 0.82 | BTK (0.85) | BTKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421854-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2421854-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885CLK2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.